Protocol Ledger

NCT05897424 · Phase II · ACTIVE NOT RECRUITING

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Interventional Phase II clinical trial protocol NCT05897424 sponsored by Sanofi in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-20 Enrollment: 185 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05897424
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)185 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05897424
Protocol FieldVerified Registry Value
NCT IdentifierNCT05897424
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment185 participants (ESTIMATED)
Registered Start Date2024-06-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI